MedicureTSXV:MPH +0.78%64 Days Payable is 210.28 as of Mar. 2026, which is 49% below its 10-year median of 410.52. GuruFocus rates TSXV:MPH with a GF Score™ of 64/100 and a GF Value™ of C$1.56 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 921 Drug Manufacturers companies, Medicure ranks better than 80.35% on this metric.
Medicure's average Accounts Payable for the
three
months ended in Mar. 2026 was C$10.20 Mil. Medicure's Cost of Goods Sold for the
three
months ended in Mar. 2026 was C$4.43 Mil.
Hence, Medicure's Days Payable for the
three
months ended in Mar. 2026 was 210.28.
The historical rank and industry rank for Medicure's Days Payable or its related term are showing as below:
TSXV:MPH'
s Days Payable Range Over the Past 10 Years
Min: 174.64 Med: 410.52 Max: 1489.92
Current: 174.64
During the past 13 years, Medicure's highest Days Payable was 1489.92. The lowest was 174.64. And the median was 410.52.
TSXV:MPH's Days Payable is ranked better than 80.35% of 921
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs TSXV:MPH: 174.64
Medicure's Days Payable
declined
from Mar. 2025 (281.21) to Mar. 2026 (210.28).
It may suggest that Medicureaccelerated paying its suppliers.
Medicure Days Payable Related Terms
Medicure Days Payable Historical Data
* Premium members only.
The historical data trend for Medicure's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicure Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicure's Days Payable distribution charts can be found below:
* The bar in red indicates where Medicure's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Medicure's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicure (TSXV:MPH) has a Days Payable of 210.28 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medicure and its competitors. This is 49% below median its historical median of 410.52. Over the past decade, Medicure's Days Payable has ranged from 174.64 to 1,489.92. According to the industry distribution chart, Medicure ranks #181 out of 921 companies in the Drug Manufacturers industry, placing it in the top 19.7%.
Is Medicure's Days Payable too high?
Medicure's current Days Payable of 210.28 is 49% below median its 10-year median of 410.52. Over the past 10 years, this metric has ranged from a low of 174.64 to a high of 1,489.92. The Drug Manufacturers industry median Days Payable is 90.69. Medicure's value of 210.28 is 131.9% above this industry median. Based on the distribution chart, Medicure ranks #181 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medicure has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medicure's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicure ranks #181 out of 921 companies for Days Payable. This places Medicure in the top 20% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.69. Medicure's value of 210.28 is 131.9% above this benchmark. Historically, Medicure's own Days Payable has ranged from 174.64 to 1,489.92 over the past decade. While the company's 10-year median is 410.52 vs. the industry median of 90.69, Medicure has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicure's current Days Payable of 210.28 is 131.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medicure and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicure's current Days Payable is 210.28, which is 49% below median its own 10-year median of 410.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Based on GuruFocus' analysis, Medicure (TSXV:MPH) is currently considered Modestly Undervalued. The stock's GF Value™ is C$1.56, compared to a current price of C$1.29 — trading 17.3% below its estimated fair value. The current Days Payable is 210.28, which is 49% below median its 10-year median of 410.52 and 131.9% above the Drug Manufacturers industry median of 90.69. Medicure's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Medicure (TSXV:MPH), the current Days Payable is 210.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicure (TSXV:MPH) Overvalued in 2026?
Based on GuruFocus' analysis, Medicure stock appears to be undervalued.
The current stock price of C$1.29 is trading 17.3% below its estimated GF Value™ of C$1.56.
GuruFocus considers Medicure to be Modestly Undervalued.
Key valuation signals for TSXV:MPH:
Days Payable: 210.28 (49% below median its 10-year median of 410.52)
GF Value™: C$1.56 vs. price of C$1.29 (17.3% below fair value)
Industry Position: 131.9% above the Drug Manufacturers median (#181 of 921)
No single metric tells the full story. See the TSXV:MPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
64GF Score
Get the complete analysis for TSXV:MPH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:MPH has been successfully added to your 
